The phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with sorafenib in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
The phase III ALTA-1L trial evaluating Alunbrig (brigatinib) versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who had not received a prior ALK inhibitor demonstrated reduced risk of disease progression or death.
City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
Duke Cancer Institute researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.
Men who seek treatment at a multidisciplinary prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines, an MD Anderson Cancer Center study found.
Within a cohort of 106,732 cancer survivors diagnosed between 2000 and 2015, researchers at the University of California San Diego determined rates of persistent post-treatment opioid use, diagnoses of opioid abuse or dependence, and admissions for opioid toxicity.
A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
The phase III Takeda TOURMALINE-MM4 study met its primary endpoint of progression-free survival in multiple myeloma not treated with stem cell transplantation.
A phase II study (NCT03491683) of newly diagnosed glioblastoma multiforme combining Inovio's INO-5401 and INO-9012 in combination with Libtayo (cemiplimab) showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months measured from the time of their first dose (n = 52), substantially exceeding historical standard-of-care data.
NCI and AppliedVR have formed a collaboration to evaluate whether virtual reality can address the underlying anxiety often experienced by many patients with terminal cancer.
